Immunomodulatory therapies and low dose azathioprine reverse partially and significantly visual and neurologic deficits in progressive forms of multiple sclerosis: Further observations

Acta Myologica

Volumn 21, Issue DEC., 2002, Pages 144-150

  Milder, Dan G ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b NONE   (Australia)

Author keywords

Azathioprine; C3d; Immunomodulatory therapies; Microgliocyte reversal; Progressive multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; COMPLEMENT COMPONENT C3D; GLATIRAMER; INTERFERON BETA SERINE; MYELIN;

ADULT; ARTICLE; BALANCE DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MALE; MICTURITION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; SENSATION; STRENGTH; TREATMENT OUTCOME; VISUAL DISORDER;

EID: 0036920864     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46.
2. Milder DG. Partial and significant reversal of progressive visual and neurologic deficits in multiple sclerosis: a possible therapeutic effect. Clini Exper Ophthalmol 2002;30:363-366.
3. Milder DG. Immunomodulatory therapies and low dose Azathioprine reverse progressive visual and neurologic deficits in multiple sclerosis. Acta Myol 2002;2:114-21.
4. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979;5:22-31.
5. Sarchielli P, Orlacchio A, Vicinanza F, et al. Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. J Neuroimmunol 1997;80:76-86.
6. Van der Laan LJ, Ruuls SR, Weber KS, et al. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumour necrosis factor-alpha and nitric oxide. J Neuroimmunol 1996;70:145-52.
7. England JD, Gamboni F, Levinson SR, et alE. Changed distribution of sodium channels along demyelinated axons. Proc Natl Acad Sci USA 1990;87:6777-80.
8. Stevenson VL, Miller DH. Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis. Multiple Sclerosis 1999;5:268-72.
9. Prineas JW, Kwon EE, Cho ES, et al. immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001;50:646-57.
10. Mathews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119:715-22.
11. Bjartmar C, Yin X, Trapp BD. Axonal pathology in myelin disorders. J Neurocytol 1999;28:383-95.
12. Prineas JW, Barnard RO, Revesz T, et al. Multiple sclerosis. Pathology of recurrent lesions. Brain. 1993;116:681-93.
13. European Study Group on Interferon beta-1b in Secondary progressive MS. placebo-controlled multicentre trial of Interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7.
14. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051-5.
15. Chen M, Gran B, Costello K, et al. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Multiple Sclerosis 2001;7:209-19.
16. Sarvetnick N, Liggit D, Pitt SL, et al. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. Cell 1988;52:773-82.
17. Ulvestad E, Williams K, Vedeler C, et al. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J Neurologic Sci 1994;121:125-31.
18. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996;272:50-3.
19. McGeer PL, Akiyama H, Itagaki S, et al. Activation of the classic complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989;107:341-6.
20. Yamada T, McGeer PL, McGeer EG. Lewy bodies in Parkinson's disease are recognised by antibodies to complement proteins. Acta Neuropathol 1992;84:100-4.
21. McGeer PL, McGeer EG, Kawamata T, et al. Reactions of the immune system in chronic degenerative neurological diseases. Can J Neurol Sci 1991;18 (Suppl 3):376-9.
22. Baudouin C, Peyman GA, Fredi-Reygrobollet D, et al. Immunohistochemical study of subretinal membranes in age-related macular degeneration. Japan J Ophthalmol 1992;36:443-51.